Arca
Skip to content
Tools
Tools

LEPR: Leptin receptor

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Receptor for hormone LEP/leptin (Probable).

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who Is On It, and How Far Along

Every drug ChEMBL records acting on LEPR, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Protein or peptide

Approved1

  • Metreleptin

Phase 30

    Phase 21

    • Mibavademab

    Phase 10

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      MetreleptinApprovedChiesi FarmaceuticiProtein or peptideAgonistLeptin receptor agonist9Boxed warning
      MibavademabPhase 2RegeneronAntibodyAgonistLeptin receptor agonist3—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
      A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic AmenorrheaMibavademabPhase 2RecruitingRegeneron Pharmaceuticals2025-11-19
      Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized LipodystrophyMibavademabPhase 3RecruitingRegeneron Pharmaceuticals2025-10-24
      A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and AdultsMibavademabPhase 3RecruitingRegeneron Pharmaceuticals2025-10-24
      Open-label Extension Study to Evaluate Metreleptin in Patients With Partial LipodystrophyMetreleptinPhase 3RecruitingChiesi Farmaceutici S.p.A.2024-11-07
      Open-label Study to Evaluate Metreleptin in Patients With Partial LipodystrophyMetreleptinPhase 4RecruitingAmryt Pharma2024-07-03
      Metreleptin in Anorexia NervosaMetreleptinPhase 2RecruitingGabriella Milos2024-03-12
      Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With LipodystrophyMetreleptin—RecruitingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2022-06-15
      Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)MetreleptinPhase 2Active, not recruitingUniversity of Michigan2022-04-28
      MEASuRE: Metreleptin Effectiveness And Safety RegistryMetreleptin—RecruitingChiesi Farmaceutici S.p.A.2014-12-25
      Compassionate Use of Metreleptin in Previously Treated People With Generalized LipodystrophyMetreleptinPhase 3Active, not recruitingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2014-10-13
      Compassionate Use of Metreleptin in Previously Treated People With Partial LipodystrophyMetreleptinPhase 2Active, not recruitingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2014-10-13

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Obesity due to leptin receptor gene deficiency
      0.74
      Lipodystrophy
      0.54
      Type 2 diabetes mellitus
      0.51
      Obesity disorder
      0.47
      Abnormality of the skeletal system
      0.42
      Familial partial lipodystrophy
      0.39
      Generalized lipodystrophy
      0.37
      Liver disorder
      0.37

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5913, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P48357, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.